This platform enables ultra-sensitive detection of cardiac troponin I, supporting early identification of myocardial injury and acute cardiovascular events. The technology integrates aptamer-engineered DNA nanostructures with programmable molecular signal amplification strategies, including hybridization chain reaction–based assembly, to generate highly detectable biosensing responses at clinically relevant low biomarker concentrations. These amplified molecular interactions produce multimodal outputs, including optical colorimetric signals and surface-enhanced Raman scattering signatures, enabling both rapid screening and precise quantitative analysis.
Patient-derived samples are processed through an integrated molecular assay workflow, and the resulting signal patterns are interpreted using machine-learning-driven analytics to enhance diagnostic accuracy, classify disease states, and support clinical decision pathways. By uniting molecular-level sensing precision, scalable assay architecture, and intelligent data interpretation, this platform establishes a next-generation diagnostic framework that bridges high-performance laboratory biomarker detection with accessible, real-time cardiovascular risk assessment and early intervention.